Insulin Autoantibodies (IAA) (Endocrine Sciences)

CPT: 86337
Print Share


  • IAA
  • Insulin Antibodies

Expected Turnaround Time

7 - 12 days

Related Documents

Specimen Requirements


Serum, frozen


0.5 mL

Minimum Volume

0.2 mL (Note: This volume does not allow for repeat testing.)


Red-top tube or gel-barrier tube


Transfer the serum into a LabCorp PP transpak frozen purple tube tube with screw cap (LabCorp N° 49482). Freeze immediately and maintain frozen until tested. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.

Storage Instructions


Stability Requirements



Room temperature

2 days


3 days


2 years

Freeze/thaw cycles

Stable x6

Patient Preparation

No radioactive isotopes should be administered 24 hours prior to venipuncture.

Causes for Rejection

Radioactive isotopes administered 24 hours prior to venipuncture

Test Details


Insulin-I125 binding capacity

Additional Information

Type 1 diabetes, commonly referred to as insulin-dependent diabetes (IDDM), is caused by pancreatic beta-cell destruction that leads to an absolute insulin deficiency.1 The clinical onset of diabetes does not occur until 80% to 90% of these cells have been destroyed. Prior to clinical onset, type 1 diabetes is often characterized by circulating autoantibodies against a variety of islet cell antigens, including glutamic acid decarboxylase (GAD), tyrosine phosphatase (IA2), and insulin.2-5 The autoimmune destruction of the insulin-producing pancreatic beta cells is thought to be the primary cause of type 1 diabetes. The presence of these autoantibodies provides early evidence of autoimmune disease activity, and their measurement can be useful in assisting the physician with the prediction, diagnosis, and management of patients with diabetes. Insulin is the only beta-cell specific autoantigen thus far identified.4-6 Antibodies to insulin are found predominantly, though not exclusively, in young children developing type 1 diabetes. In insulin-naive (untreated) patients, the prevalence of antibodies to insulin is almost 100% in very young individuals and almost absent in adult onset of type 1 diabetes. Because the risk of diabetes is increased with the presence of each additional autoantibody marker, the positive predictive value of insulin antibody measurement is increased when measured in conjunction with antibodies to GAD and IA-2.2-4


1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997 Jul; 20(7):1183-1197. 9203460
2. Bonifacio E, Bingley PJ. Islet autoantibodies and their use in predicting insulin-dependent diabetes. Acta Diabetol. 1997 Oct; 34(3):185-193 (review). 9401639
3. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996 Jul; 45(7):926-933. 8666144
4. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: Strategies based on combinations of autoantibody markers. Diabetes. 1997 Nov; 46(11):1701-1710. 9356015
5. Sepe V, et al. Islet-related autoantigens and the pathogenesis of diabetes mellitus. In: Leslie RDG, ed. Molecular Pathogenesis of Diabetes Mellitus. 1997; 22:68-89.
6. Greenbaum CJ, Palmer JP, Kuglin B, Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: Results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab. 1992 May; 74(5):1040-1044. 1569152


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
141598 Insulin Antibodies 8072-1 141600 Insulin Antibodies uU/mL 8072-1

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at